quinazolines has been researched along with amyloid beta-peptides in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, RS; Baxter, EW; Berthelot, DJ; Bischoff, F; Boyd, RE; Braeken, M; Brenneman, DE; Bruinzeel, WD; Conway, KA; Huang, Y; Jordan, AD; Kennis, L; Luo, C; Masure, S; Mercken, MH; Parker, MH; Pieters, SM; Qu, J; Reitz, AB; Reynolds, CH; Scott, MK; Tounge, BA; Winter, HL | 1 |
| Mohamed, T; Rao, PPN | 1 |
2 other study(ies) available for quinazolines and amyloid beta-peptides
| Article | Year |
|---|---|
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Caco-2 Cells; Cell Membrane Permeability; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Humans; Hydrogen Bonding; Models, Molecular; Molecular Conformation; Mutation; Oligopeptides; Peptide Fragments; Quinazolines; Rats; Stereoisomerism; Structure-Activity Relationship | 2007 |
2,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
Topics: Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Quinazolines; Structure-Activity Relationship | 2017 |